Vyleesi (Bremelanotide) Pediatric Dosing: Why No Under-12 Dose Exists

Bremelanotide Is Not Approved for Pediatric Use

There is no pediatric dosing regimen for bremelanotide. The FDA-approved prescribing information restricts its use to premenopausal women with generalized acquired HSDD, a diagnosis that by definition applies to adults who previously had normal sexual desire. The label states explicitly that safety and effectiveness have not been established in pediatric patients.

Bremelanotide (marketed as Vyleesi by Palatin Technologies) received FDA approval in June 2019 as a 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity [1]. The entire clinical development program enrolled women between the ages of 21 and 65. No dose-finding, pharmacokinetic, or safety study has ever been conducted in patients younger than 18, let alone children under 12. The drug's mechanism of action, its activation of melanocortin-4 receptors (MC4R) in the central nervous system, targets neural pathways involved in adult sexual response. These pathways are not clinically relevant in prepubertal children, and stimulating them in a developing brain raises serious safety concerns that no researcher has proposed studying.

The absence of a pediatric dose is not an oversight or a gap in the evidence. It reflects the biological reality that HSDD does not occur in prepubertal children, and the pharmacological reality that activating central melanocortin receptors in a growing child could interfere with appetite regulation, cardiovascular stability, and neuroendocrine development.

Why HSDD Cannot Be Diagnosed in Children

HSDD requires a prior baseline of normal sexual desire that has decreased, causing personal distress. Children under 12 have not undergone puberty and do not have an established baseline of sexual desire. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) reclassified the condition as Female Sexual Interest/Arousal Disorder and requires symptoms to persist for a minimum of six months in an adult context.

No validated screening tool for HSDD exists for pediatric populations. The Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS) were designed for and validated in adult women. Applying an adult sexual health diagnosis to a prepubertal child would be clinically inappropriate and outside the scope of any published guideline from the Endocrine Society or the American College of Obstetricians and Gynecologists.

The RECONNECT trials (Phase 3, N=1,247 combined) used the FSFI desire domain and co-primary endpoints measuring sexually satisfying events and sexual desire scores, all instruments that presuppose adult sexual function [1]. Extrapolating these outcomes to a child has no clinical basis.

The RECONNECT Trial Population: Adults Only

The RECONNECT studies (Study 301 and Study 302) enrolled premenopausal women aged 21 and older with HSDD diagnosed by a clinician using the DSDS [1]. Mean participant age was approximately 39 years. The trials excluded postmenopausal women, men, and anyone under 21.

In the pooled analysis published in Obstetrics & Gynecology (2019), bremelanotide 1.75 mg produced a statistically significant improvement in the FSFI desire domain score compared to placebo (least-squares mean difference 0.5, P<0.001) and a significant increase in satisfying sexual events [1]. These results tell us nothing about how the drug would behave in a child's body. Children under 12 differ from adult women in hepatic metabolism, renal clearance, body composition, blood-brain barrier permeability, and receptor density across virtually every organ system.

No pediatric pharmacokinetic bridging study exists for bremelanotide. Without one, even theoretical weight-based dose extrapolation would be speculation, not medicine.

Melanocortin Receptor Biology and Pediatric Risk

Bremelanotide activates MC4R and MC1R. MC4R is distributed throughout the hypothalamus, where it regulates not only sexual arousal but also energy homeostasis, appetite, and autonomic cardiovascular function [2]. In adults, transient MC4R activation produces predictable side effects: nausea (40% of patients in RECONNECT), flushing (20%), and a transient rise in blood pressure averaging 6 mmHg systolic that resolves within 12 hours [1].

In a child under 12, the MC4R system is actively shaping growth trajectories. Loss-of-function MC4R mutations are the most common monogenic cause of severe childhood obesity, affecting approximately 5-6% of children with early-onset obesity [3]. This tells us the receptor is load-bearing for normal pediatric development. Pharmacologically activating it with an exogenous agonist could suppress appetite acutely, alter weight gain patterns, disrupt hypothalamic-pituitary-adrenal signaling, or trigger unpredictable cardiovascular responses in a system that lacks the homeostatic reserves of an adult.

MC1R activation drives melanogenesis. In RECONNECT, focal skin hyperpigmentation occurred in roughly 1% of adult participants [1]. Pediatric skin, which has higher cell turnover and different melanocyte density, could respond differently. No data exist to quantify this risk.

The blood pressure signal is particularly concerning. The FDA label includes a boxed warning-level precaution about blood pressure increases and recommends against use in patients with uncontrolled hypertension or known cardiovascular disease [4]. Pediatric blood pressure norms are percentile-based and age-dependent. A 6 mmHg systolic rise that is clinically insignificant in a 35-year-old woman could push a 7-year-old above the 95th percentile threshold for stage 1 hypertension, per AAP guidelines [5].

FDA Pediatric Study Requirements and Bremelanotide

The Pediatric Research Equity Act (PREA) of 2003 generally requires sponsors to submit pediatric study plans for new molecular entities. There are exemptions. The FDA can grant a full waiver when a drug treats a condition that does not occur in the pediatric population, or when studies would be impossible or highly impractical to conduct [6].

Bremelanotide falls squarely into the waiver category. HSDD is an adult condition. There is no pediatric disease that bremelanotide is being investigated for, and no Investigational New Drug (IND) application for a pediatric indication appears in the ClinicalTrials.gov registry as of May 2026. The FDA did not issue a Written Request or Pediatric Study Plan requirement for bremelanotide.

This is the correct regulatory outcome. A drug that treats adult female sexual dysfunction has no pediatric population to study. Mandating trials in children for a condition they cannot have would expose minors to risk with zero potential benefit, a violation of the ethical framework outlined in the Declaration of Helsinki and the Belmont Report principles of beneficence and justice [7].

What If a Child Is Accidentally Exposed?

Accidental ingestion or injection is the only realistic pediatric exposure scenario. The Vyleesi auto-injector delivers a fixed 1.75 mg dose subcutaneously. If a child were accidentally injected, the expected effects based on adult pharmacology would include nausea, vomiting, flushing, and a transient blood pressure increase.

No published case reports of pediatric bremelanotide exposure exist. The FDA Adverse Event Reporting System (FAERS) does not contain pediatric bremelanotide cases as of early 2026 [4]. In an accidental exposure scenario, standard poison control protocols apply: contact Poison Control (1-800-222-1222 in the United States), monitor blood pressure and heart rate, and observe for nausea or emesis.

The drug's half-life is approximately 2.7 hours in adults [4]. Assuming faster weight-adjusted clearance in a child, effects would likely resolve within 6 to 8 hours, though this is extrapolation, not evidence. No antidote exists. Treatment would be supportive and symptom-directed.

Auto-injector storage matters. The Vyleesi pen should be kept in its original carton, at room temperature, out of reach of children. The device requires removal of a safety cap and firm pressure against the skin to fire, which provides some protection against casual handling but not against a determined child.

Comparison With Other HSDD Therapies and Age Restrictions

Flibanserin (Addyi) is the other FDA-approved HSDD treatment. Like bremelanotide, it carries no pediatric indication and has never been studied in children [8]. Flibanserin is a daily oral 5-HT1A agonist/5-HT2A antagonist approved for premenopausal women. Its label also states that safety and efficacy in pediatric patients have not been established.

Neither testosterone (off-label for HSDD in postmenopausal women per Endocrine Society guidelines) nor any other pharmacotherapy for low sexual desire has a pediatric indication [9]. The entire therapeutic category is adult-only because the condition is adult-only.

This consistency across the drug class reinforces the point: the absence of pediatric bremelanotide dosing is not a gap waiting to be filled. It is the expected state for a drug whose target condition does not exist in children.

Off-Label Melanocortin Research in Pediatrics: A Different Drug

Setmelanotide (Imcivree), a different MC4R agonist, does have a pediatric indication, but for a completely different condition. The FDA approved setmelanotide in 2020 for chronic weight management in patients aged 6 and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing [10]. Setmelanotide dosing in children starts at 1 mg subcutaneously daily and titrates to 3 mg.

Bremelanotide and setmelanotide share a receptor target but differ in selectivity, dosing frequency, indication, and safety monitoring requirements. The existence of a pediatric MC4R agonist for obesity does not create a rationale for using bremelanotide in children. The two drugs have different binding profiles, different titration protocols, and completely different risk-benefit calculations. Confusing them would be a category error.

Prescribing and Dispensing Safeguards

Pharmacies dispensing Vyleesi verify the patient's age and sex as part of standard prescription processing. The drug requires a prescription, carries no REMS (Risk Evaluation and Mitigation Strategy) program, but its narrow indication creates a natural guardrail: a prescription for bremelanotide written for a child would raise immediate red flags at the pharmacy level.

Prescribers should document the patient's menopausal status and HSDD diagnosis before writing a bremelanotide prescription. The ACOG Practice Bulletin on Female Sexual Dysfunction recommends a thorough evaluation including relationship factors, medication review, and psychological assessment before pharmacotherapy [11]. None of these evaluation steps apply to a prepubertal child.

Insurance coverage adds another layer. Most payers restrict Vyleesi to premenopausal women with a documented HSDD diagnosis and prior therapy failure. A claim for a pediatric patient would be denied on the basis of age, indication, or both.

A Note on Adolescents (Ages 12 to 17)

While this article focuses on children under 12, the same principles apply to adolescents. No bremelanotide dosing exists for patients aged 12 to 17. The RECONNECT trials set the lower age limit at 21, not 18. Even if HSDD could theoretically be diagnosed in a post-pubertal 17-year-old (a clinically debatable scenario), no efficacy or safety data support bremelanotide use in this age group.

The Society for Adolescent Health and Medicine has published guidance on adolescent sexual health that focuses on education, contraception, and STI prevention, not on pharmacotherapy for desire disorders [12]. The absence of bremelanotide from any adolescent health guideline is not a gap in the literature. It reflects clinical consensus.